You are here: Industry Insights > Bristol Myers Squibb

News List

Bristol Myers Squibb announces positive topline results from True North trial evaluating Zeposia in pharmaceutical-business-review
June 05, 2020
Bristol Myers Squibb announced results from True North, a pivotal Phase 3 trial evaluating oral Zeposia (ozanimod) as an induction and maintenance therapy for adult patients with moderate to severe ulcerative colitis.
Bristol Myers Squibb receives EC approval for Zeposia in adults with RRMS with active disease pharmaceutical-business-review
June 01, 2020
Bristol Myers Squibb announced that the European Commission (EC) has approved Zeposia (ozanimod) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.
bluebird bio Amends CAR-T Collaboration Agreement contractpharma
May 19, 2020
Bristol Myers Squibb assumes responsibility for vector manufacturing in ex-U.S. territories.
FDA accepts for priority review Bristol Myers Squibb’s application for CC-486 for maintenance treatm pharmaceutical-business-review
May 08, 2020
Bristol Myers Squibb announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for CC-486 for the maintenance treatment of adults in remission with acute myeloid leukemia (AML).
Bristol Myers says Opdivo performs well in kidney, lung cancer trials expresspharma
April 22, 2020
Opdivo is one of Bristol’s top-selling drugs, but sales of the drug have slowed in recent years as it has been eclipsed by Merck & Co’s rival drug Keytruda.
Intensity Therapeutics signs clinical collaboration agreement with Bristol Myers Squibb for advanced solid tumors pharmaceutical-business-review
April 17, 2020
Intensity Therapeutics announced it has entered into a clinical trial collaboration agreement with Bristol Myers Squibb Company.
Bristol Myers Squibb, Acceleron get FDA nod for Reblozyl to treat anaemia with lower-risk MDS pharmaceutical-business-review
April 07, 2020
Bristol Myers Squibb (BMS) and Acceleron Pharma have secured approval from the US Food and Drug Administration (FDA) for Reblozyl (luspatercept-aamt) to treat anaemia in adults with lower-risk myelodysplastic syndromes (MDS).
Bristol Myers Squibb and bluebird bio submit BLA for Idecabtagene Vicleucel to FDA pharmaceutical-business-review
April 03, 2020
Bristol Myers Squibb and bluebird bio submitted their Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA).
U.S. Food and Drug Administration approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) for patients with hepatocellular carcinoma (HCC) previously treated with sorafenib worldpharmanews
March 12, 2020
Bristol Myers Squibb Company announced that Opdivo (nivolumab) 1 mg/kg plus Yervoy (ipilimumab) 3 mg/kg (injections for intravenous use) was approved by the U.S. Food and Drug Administration (FDA) to treat hepatocellular carcinoma (HCC) in patients ...
Regen Addresses Potential Impact of Bristol Myers Squibb's $2.3 Billion Acquisition of IFM americanpharmaceuticalreview
August 11, 2017
On August 3, 2017 Bristol Myers Squibb (BMS) announced that it had entered into an agreement to acquire IFM Therapeutics, a smaller biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, au

Previous page 1 2 3 4 Next page